NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
- BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed in partnership with LigaChem Biosciences (LCB) (KOSDAQ: 141080), and biomarker data from the NC410 combination study with pembrolizumab in patients with immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC). The data will be presented during poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting.
- 11/05/2024
|
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
- BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions.
- 10/04/2024
|
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
- BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. The trial, which is evaluating the combination in ovarian cancer and immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC), demonstrated clinical activity in these hard-to-treat cancers. The data were presented by clinical trial investigators Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center (ovarian) and Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (CRC). The presentations are available on the NextCure website (www.nextcure.com).
- 09/16/2024
|
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
- 06/20/2024
|
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
- BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
- 05/30/2024
|
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
- BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.
- 05/02/2024
|
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S.
- 04/24/2024
|
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
- Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74
- 04/08/2024
|
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
- BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
- 04/04/2024
|
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
- BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.
- 04/02/2024
|
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
- The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.
- 03/23/2024
|
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
- BELTSVILLE, Md. – March 21, 2024, March 21, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update and reported full year 2023 financial results.
- 03/21/2024
|
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
- BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies” in the journal Science Advances, published by the American Association for the Advancement of Science. The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
- 03/05/2024
|
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
- BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (COPD), at the Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy.
- 01/18/2024
|
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
- NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 12/25/2023
|
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
- BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats” in JMBR Plus, a journal of the American Society for Bone and Mineral Research (ASBMR). The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.
- 12/21/2023
|
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
- NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
- 12/15/2023
|
NextCure Provides Year-End Clinical Pipeline Updates
- BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline.
- 12/14/2023
|
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
- BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.
- 11/20/2023
|
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
- BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “LAIR-1 Agonism as a Therapy for Acute Myeloid Leukemia” in the Journal of Clinical Investigation. The data demonstrate that NC525 induces cell death in acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs) through leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) agonism by driving a unique apoptotic signaling pathway.
- 11/15/2023
|
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
- NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/07/2023
|
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
- BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported third quarter 2023 financial results.
- 11/02/2023
|
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
- Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting
- 10/17/2023
|
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease
- BELTSVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, including neuroinflammatory disease, today announced the presentation of preclinical data relating to NC181, a novel humanized antibody targeting ApoE4, for the treatment of Alzheimer's disease (AD), at the 2nd Annual Neurodegeneration Targets, Drug Discovery for Progressive Central Nervous System Disorders conference.
- 09/26/2023
|
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
- • Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore
- 09/12/2023
|
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Monday, September 11th, at 5:00 pm ET.
- 08/31/2023
|
NextCure to Present at the JMP Securities Life Sciences Conference
- BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
- 05/09/2023
|
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
- BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
- 04/11/2023
|
NextCure to Present at SVB Securities Global Biopharma Conference
- BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
- 02/07/2023
|
NextCure to Present at Upcoming Investor Conferences
- BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the following investor conferences:
- 11/22/2022
|
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
- BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans. NC525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and is being developed for the treatment of advanced myeloid leukemia (AML).
- 11/03/2022
|
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
- NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/05/2022
|
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
- BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Ladenburg Thalmann Healthcare Conference in New York City on Thursday, September 29th at 10 am ET.
- 09/22/2022
|
NextCure to Present at the JMP Securities Life Sciences Conference
- BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 15th at 2 pm ET.
- 06/08/2022
|
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
- BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday February 16th at 10:40 am ET.
- 02/08/2022
|
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
- BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th.
- 11/22/2021
|
2 Net Current Asset Value Stocks to Consider
- There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share prices to near or above the liquidation value.
- 10/29/2021
|
NextCure Announces Three New Members of its Scientific Advisory Board
- BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB). Ethan Shevach, M.D., will retire from the SAB. Drs. Lieping Chen, M.D., Ph.D., Mario Sznol, M.D., and Stephen Miller, Ph.D., will continue to serve on the SAB.
- 10/19/2021
|
NextCure Announces Publication of Preclinical Data for NC410
- BELTSVILLE, Md., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal Frontiers in Immunology, which indicate that collagen fragments produced in cancer can mediate T cell suppression through LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells. This immune suppression could be reversed by LAIR-2, a natural decoy of LAIR-1, and NC410, a LAIR-2 fusion protein. NC410 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors and is a first-in-class immunomedicine designed to block LAIR-1-mediated immune suppression.
- 10/07/2021
|
NextCure Announces New Appointments to its Board of Directors
- BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.
- 10/04/2021
|
NXTC Stock Price: Why It Increased Over 12%
- The stock price of NextCure Inc (NASDAQ: NXTC) increased by over 12% in the previous trading session. This is why it happened.
- 10/02/2021
|
NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting
- BELTSVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two clinical studies and one research study will be presented during oral and poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Washington, D.C., and in a virtual platform on November 10-14, 2021. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a LAIR-2 fusion protein, in patients with advanced/metastatic solid tumors. In addition, in collaboration with the National Cancer Institute at the National Institutes of Health, non-clinical data will be presented from a research study evaluating NC410's impact on T cell activation, myeloid cell polarization and anti-tumor activity.
- 10/01/2021
|
NextCure: Large Upside With Downside Protected By Cash Pile
- The stock is left for dead, trading significantly below cash which creates a margin of safety. Significant data on all 3 drugs is due in the next 9 months.
- 09/29/2021
|
NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th.
- 09/07/2021
|
NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings
- NextCure Inc (NASDAQ: NXTC) has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody. The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose.
- 07/07/2021
|
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
- BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.
- 07/06/2021
|
NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies
- NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tumors.
- 06/22/2021
|
NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
- BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal eLife establishing NC410 as a novel immunomedicine targeting immune-excluded regions of collagen-rich tumors and enabling normalization of the tumor immune microenvironment. NC410, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors, is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells.
- 06/21/2021
|
NextCure to Present at the JMP Securities Life Sciences Conference
- BELTSVILLE, Md., June 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17th at 1:30 pm Eastern time.
- 06/10/2021
|
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator, Martin Gutierrez, M.D., Director, Phase 1 Program and Co-Chair of Thoracic Oncology at Hackensack University Medical Center, will present a Trials in Progress poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 05/19/2021
|
NextCure Reports First Quarter 2021 Financial Results
- BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial results and provided a business update.
- 05/06/2021
|
A Trio of Net Current Asset Value Stock Picks
- Short-term investors may want to have a look at these businesses
- 04/13/2021
|
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
- BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer.
- 04/10/2021
|
NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference
- BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on April 13th at 12:45 pm Eastern time.
- 04/07/2021
|
REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021
- BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.
- 03/02/2021
|
NextCure to Host Virtual R&D Update Event on March 4, 2021
- BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.
- 02/26/2021
|
LONG-TERM INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - February 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ("NextCure" or "the Company") (NASDAQ: NXTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities in 2019, are encouraged to contact the firm immediately.If...
- 02/11/2021
|
LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.
- 01/27/2021
|
Dr. Han Myint Appointed as NextCure's Chief Medical Officer
- BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure's product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.
- 01/14/2021
|
The 10 Worst Performing Stocks of 2020
- These companies are eager to say good riddance to the year that was.
- 12/29/2020
|
LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “the Company”) (NASDAQ: NXTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities in 2019, are encouraged to contact the firm immediately. If you are a shareh
- 12/18/2020
|
NextCure Provides Updates on NC318 Clinical Program
- BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.
- 12/17/2020
|
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
- BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st.
- 11/23/2020
|
NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
- NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
- 11/20/2020
|
Final Deadline Alert: Rosen, Global Investor Counsel, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action - NXTC
- New York, New York--(Newsfile Corp. - November 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure...
- 11/19/2020
|
FRIDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (NASDAQ: NXTC) ("NextCure" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 5, 2019 and July 14, 2020,...
- 11/18/2020
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (NASDAQ: NXTC) ("NextCure" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 5, 2019 and July 14, 2020,...
- 11/17/2020
|
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (NASDAQ: NXTC) ("NextCure" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 5, 2019 and July 14, 2020, inclusive...
- 11/16/2020
|
ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - NXTC
- NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's...
- 11/14/2020
|
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (NASDAQ: NXTC) ("NextCure" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 5, 2019 and July 14, 2020, inclusive...
- 11/13/2020
|
ROSEN, A TOP RANKED FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action - NXTC
- New York, New York--(Newsfile Corp. - November 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure...
- 11/07/2020
|
NextCure Reports Third Quarter 2020 Financial Results
- BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2020 financial results and provided a business update.
- 11/05/2020
|
ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - NXTC
- NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's...
- 10/28/2020
|
NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.
- NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...
- 10/27/2020
|
SHAREHOLDER ALERT: KODK BLNK NXTC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- October 08, 2020 (ACCESSWIRE via COMTEX) --
NEW YORK, NY / ACCESSWIRE / October 8, 2020 / The Law Offices of Vincent Wong announce that class actions have...
- 10/08/2020
|
SHAREHOLDER ALERT: ODT NXTC FLDM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- October 05, 2020 (ACCESSWIRE via COMTEX) --
NEW YORK, NY / ACCESSWIRE / October 5, 2020 / The Law Offices of Vincent Wong announce that class actions have...
- 10/05/2020
|
LAWSUITS FILED AGAINST BLNK, NXTC and TCMD - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- October 02, 2020 (ACCESSWIRE via COMTEX) --
NEW YORK, NY / ACCESSWIRE / October 2, 2020 / Jakubowitz Law announces that securities fraud class action...
- 10/02/2020
|
CLASS ACTION UPDATE for BIDU, CLNC and NXTC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- September 30, 2020 (ACCESSWIRE via COMTEX) --
NEW YORK, NY / ACCESSWIRE / September 30, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits...
- 09/30/2020
|
Shareholder Alert: Robbins LLP Announces That An Investor of NextCure, Inc. (NXTC ) Filed a Class Action Complaint Against the Company
- Shareholder rights law firm Robbins LLP announces that an investor of NextCure, Inc. (NASDAQ: NXTC) filed a class action against the Company for: (i)
- 09/24/2020
|
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against NextCure Inc.
- Scott+Scott Attorneys at Law LLP Files Securities Class Action Against NextCure, Inc.
- 09/22/2020
|
What's Next For NextCure
- Today, we look at a small biotech concern that has entered 'Busted IPO' territory after a recent trial setback.
- 08/24/2020
|
NextCure Reports Second Quarter 2020 Financial Results
- BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2020 financial results and provided a business update. “Despite our recent announcement that we did not see sufficient clinical activity required for advancement in our initial non-small cell lung cancer and ovarian cancer Phase 2 cohorts, we remain encouraged about the NC318 single agent activity we have seen in patients with both non-small cell lung and head and neck cancers. We are working diligently in hopes of better understanding Siglec-15 biology and evaluating biomarkers that may provide a focused path forward. We anticipate having more information by the end of this year,” said Michael Richman, NextCure’s president and chief executive officer. “We recently initiated the Phase 1 portion of a Phase 1/2 clinical trial of NC410, our second product candidate, and expect to have initial clinical data for that trial in the second half of 2021. We remain highly committed to our goal of bringing novel immunomedicines to patients and remain focused on advancing our current clinical and preclinical programs.”Business Highlights and upcoming milestones * Observed one confirmed partial response in head and neck squamous cell carcinoma (HNSCC), and advanced this indication to the stage 2 portion of the Simon 2-stage trial of NC318. * Continued enrolling new patients in the HNSCC and triple-negative breast cancer cohorts of the NC318 monotherapy trial. * Reported initial biomarker data from the Phase 1 portion of the NC318 Phase 1/2 monotherapy clinical trial at the virtual American Society of Clinical Oncology Annual Meeting. * Initiated the Phase 1 portion of a Phase 1/2 clinical trial for NC410.Financial Results for Quarter Ended June 30, 2020 * Cash, cash equivalents and marketable securities as of June 30, 2020 were $309.3 million, compared to $334.6 million as of December 31, 2019. The decrease of $25.3 million primarily reflects cash used to fund operations of $23.0 million and cash used to purchase fixed assets of $4.3 million. * Research and development expenses were $11.1 million for the quarter ended June 30, 2020, as compared to $7.6 million for the quarter ended June 30, 2019. The increases primarily reflect an increase in headcount, clinical research costs for NC318 and NC410, and expenses for lab supplies and services for NC318, NC410, our other early stage programs and discovery activities. * General and administrative expenses were $4.7 million for the quarter ended June 30, 2020, as compared to $2.7 million for the quarter ended June 30, 2019. The increase was primarily related to increases in personnel-related costs due to an increase in headcount, as well as increases in professional fees and insurance costs in connection with becoming a publicly traded company. * There was no revenue recognized in the quarter ended June 30, 2020 as compared to $1.4 million in the quarter ended June 30, 2019. Revenue generated in the prior year quarter was from our former research and development agreement with Eli Lilly. * Net loss was $14.5 million for the quarter ended June 30, 2020, as compared to $8.2 million for the quarter ended June 30, 2019. The increase in net loss for the quarter was primarily due to increased research and development expenses and increased general and administrative expenses from an increase in headcount.About NC318 NC318 is a first-in-class immunomedicine against S15, a novel immunomodulatory target found on highly immunosuppressive cells called M2 macrophages in the tumor microenvironment and on certain tumor types including lung, ovarian and head and neck cancers. In preclinical research, it was observed that S15 promoted the survival and differentiation of suppressive myeloid cells and negatively regulated T cell function, allowing cancer to avoid immune destruction. In preclinical studies, NC318 blocked the negative effects of S15. NextCure believes NC318 has the potential to treat multiple cancer types.About NC410 NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and dendritic cells, a type of antigen presenting cell. In preclinical research, it was observed that LAIR-1 inhibited T cell function and dendritic cell activity allowing tumor cells to grow. In preclinical studies, NC410 blocked the negative effects of LAIR-1 and promoted T cell function and dendritic cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.comForward-Looking Statements This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,” “will,” “potential,” “expects,” “believes,” “intends,” “hope,” “towards,” “forward,” “later” and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the progress and evaluation and expected timing of results of NextCure’s ongoing clinical trial of NC318, expectations regarding the potential benefits, activity, effectiveness and safety of NC318, the evaluation of biomarkers, the expected timing of results of NextCure’s ongoing clinical trial of NC410 and NextCure’s plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure’s business, including NextCure’s clinical trials, third parties on which NextCure relies and NextCure’s operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and no products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure’s FIND-IO platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change. NEXTCURE, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited, in thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Revenue: Revenue from research and development arrangement $— $1,402 $22,378 $2,759 Operating expenses: Research and development 11,130 7,643 21,708 14,156 General and administrative 4,671 2,714 8,259 4,373 Total operating expenses 15,801 10,357 29,967 18,529 Loss from operations (15,801) (8,955) (7,589) (15,770) Other income, net 1,293 734 2,814 1,394 Net loss $(14,508) $(8,221) $(4,775) $(14,376) Loss per share: Net loss per common share—basic and diluted $(0.53) $(0.61) $(0.17) $(1.92) Weighted average number of common shares—basic and diluted 27,518,129 13,498,393 27,512,528 7,472,298 Comprehensive Loss: Net loss $(14,508) $(8,221) $(4,775) $(14,376) Unrealized gain on marketable securities 2,478 — 1,935 — Total comprehensive loss $(12,030) $(8,221) $(2,840) $(14,376) NEXTCURE, INC.
- 08/06/2020
|
Reflecting on NextCure's (NASDAQ:NXTC) Share Price Returns Over The Last Year
- Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for NextCure...
- 08/05/2020
|
NextCure to Present at BTIG Virtual Biotechnology Conference
- BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BTIG Virtual Biotechnology Conference on August 11th at 9:30 am Eastern time. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.comCautionary Statement Regarding Forward-Looking Statements Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change. CONTACT: Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com
- 08/05/2020
|
Will NextCure, Inc. (NXTC) Report Negative Q2 Earnings? What You Should Know
- NextCure, Inc. (NXTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2020
|
Vident Investment Advisory LLC Buys 26,730 Shares of NextCure Inc (NASDAQ:NXTC)
- Vident Investment Advisory LLC lifted its position in NextCure Inc (NASDAQ:NXTC) by 94.3% during the second quarter, Holdings Channel reports. The institutional investor owned 55,077 shares of the company’s stock after buying an additional 26,730 shares during the quarter. Vident Investment Advisory LLC’s holdings in NextCure were worth $1,181,000 as of its most recent SEC […]
- 08/03/2020
|
NextCure (NASDAQ:NXTC) Shares Gap Down on Analyst Downgrade
- NextCure Inc (NASDAQ:NXTC) gapped down prior to trading on Tuesday after BTIG Research lowered their price target on the stock from $61.00 to $27.00. The stock had previously closed at $3.55, but opened at $8.15. BTIG Research currently has a buy rating on the stock. NextCure shares last traded at $8.94, with a volume of […]
- 07/16/2020
|
Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC)
- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) or certain of its officers and directors violated federal securities laws. If you purchased NextCure securities pursuant and/or traceable to NextCure's offering in November 2019 or have otherwise suffered a loss, realized or unrealized, you are encouraged to contact Scott+Scott attorney Jonathan Zimmerman at (888) 398-9312 for more information.
- 07/15/2020
|
Osmotica's FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
- Osmotica gets FDA approval for Droopy Eyelid Treatment. NextCure advances solid tumor trial of NC410.
- 07/13/2020
|
NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer
- BELTSVILLE, Md., July 13, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
- 07/13/2020
|
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
- U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
- 07/13/2020
|
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC410, a novel immunomedicine developed to block immune suppression mediated by an immune modulator called LAIR-1. LAIR-2 is a naturally occurring soluble version of LAIR-1, which binds to and blocks the inhibitory activity of LAIR-1 and thus acts as a decoy protein.
- 07/07/2020
|
Legal & General Group Plc Decreases Position in NextCure Inc (NASDAQ:NXTC)
- Legal & General Group Plc lessened its holdings in NextCure Inc (NASDAQ:NXTC) by 18.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,341 shares of the company’s stock after selling 546 shares during the quarter. Legal & General Group Plc’s […]
- 07/06/2020
|
NextCure Inc (NASDAQ:NXTC) Shares Sold by JPMorgan Chase & Co.
- JPMorgan Chase & Co. lowered its stake in shares of NextCure Inc (NASDAQ:NXTC) by 65.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,637 shares of the company’s stock after selling 8,704 shares during the period. JPMorgan Chase & Co.’s holdings […]
- 07/05/2020
|
NextCure, Inc. (NXTC): Are Hedge Funds Right About This Stock?
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/28/2020
|
Wellington Management Group LLP Reduces Position in NextCure Inc (NASDAQ:NXTC)
- Wellington Management Group LLP decreased its holdings in shares of NextCure Inc (NASDAQ:NXTC) by 11.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 525,887 shares of the company’s stock after selling 66,528 shares during the quarter. Wellington Management Group LLP owned […]
- 06/20/2020
|
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology (ASCO20) Annual Meeting. “Because this is a trial in progress with limited samples, we cannot draw definitive conclusions, but we believe these early biomarker data provide additional evidence of NC318 activity,” said Kevin N. Heller, M.D., NextCure’s chief medical officer.
- 05/29/2020
|
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
- 05/29/2020
|
7 High-Risk Stocks For Market Gamblers
- Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports leagues.In the meantime, some gamblers are looking to get their thrills in the stock market. But as many new traders learn the hard way, placing bets on the wrong stocks can be just as costly as picking the wrong horse at the racetrack.Here are eight Bank of America buy-rated stocks that have high volatility ratings and at least 40% upside to analyst price targets.Golar LNG (NASDAQ: GLNG) Golar LNG owns and operates one of the largest independent liquid natural gas carriers and floating storage fleets in the world.Analyst Ken Hoexter says Golar is a leader in the LNG transport and energy infrastructure business, and it has advantages over many of its competitors due to its more diversified offerings. In addition, Bank of America is bullish on long-term LNG prices as more terminals in Australia, Russia and the U.S. come online this year. Hoexter says there is upside to the company's Golar Power EBITDA over the next two years.Bank of America has a Buy rating and $15 price target for GLNG stock.Gossamer Bio Inc (NASDAQ: GOSS) Gossamer Bio is a biotech company with a pipeline of clinical and preclinical drug candidates focused on immunology, inflammation and oncology.Analyst Geoff Meacham said in March that Gossamer has several clinical candidates that have the potential to have massive total addressable markets treating a wide range of common conditions, including asthma and pulmonary arterial hypertension. Meacham said the company has a long list of potential near-term catalysts ahead that could potentially de-risk the stock and generate significant upside. He said data on BG001 in asthma is likely the biggest catalyst ahead.Bank of America has a Buy rating and $26 price target for GOSS stock.See Also: 7 Sin Stocks To Buy During The Coronavirus ShutdownLexinFintech Holdings Ltd - ADR (NASDAQ: LX) Lexin Fintech is an online consumer financing platform geared toward educated young adults in China.Analyst Eddie Lueng recently said he expects the company will shift gears from user growth in the second half of 2019 to optimizing its user acquisitions in the first half of 2020 due to the pandemic. Lueng says the company has a relatively sticky user base compared to its peers, and it's also exposed to less regulatory risk. Its user base of around 5 million people is only about 5% penetration of China's educated young adult demographic.Bank of America has a Buy rating and $19.80 price target for LX stock.Millicom International Cellular SA (NASDAQ: TIGO) Millicom is a telecom provider for nearly 50 million customers in Latin America and Africa.Analyst Rodrigo Villanueva recently said management took decisive action in preparing for the economic downturn by implementing more than $100 million in cost savings, cutting between $200 million and $300 million in capex, suspending $100 million in 2020 dividend payments and pausing $150 million in buybacks. Villanuava says prioritizing liquidity and cash is the right move, and the company's subscription-based revenue should prove relatively resilient during the downturn while the stock's valuation provides long-term upside.Bank of America has a Buy rating and $56 price target for TIGO stock.GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) GW Pharmaceuticals is a biopharmaceutical company that focuses primarily on developing cannabinoid-based drugs for a wide variety of applications. GW's Epidiolex was the first ever cannabis-based medication ever approved by the FDA.Analyst Tazeen Ahmad recently said Epidiolex's label could soon expand beyond epilepsy to tuberous sclerosis complex in the U.S., while launches in countries like Germany, the UK, France, Spain and Italy are also driving near-term revenue upside. Ahmad said Epidiolex's sales trajectory up to this point has been impressive and has closely tracked the results of Bank of America's previous doctor surveys.Bank of America has a Buy rating and $230 price target for GWPH stock.NextCure Inc (NASDAQ: NXTC) NextCure is a clinical stage biotech company developing cancer treatments.Analyst Alec Stranahan recently spoke to NextCure management following Bank of America's 2020 Healthcare Conference, and Stranahan said the COVID-19 outbreak has negatively impacted enrollment of the company's ongoing NC318 Phase II testing. In addition, studies of NC410 and NC318 have also been disrupted.Given the delays, Stranahan estimated the highly anticipated Phase II NC318 data will likely now come in the first half of 2021 rather than the fourth quarter of 2020. The massive potential of NC318 and NC410 created home run potential for investors, but the inherent risk in the early-stage trial data generates inherent risk.Bank of America has a Buy rating and $62 price target for NXTC stock.SINA Corp (NASDAQ: SINA) Sina is the owner of leading online social media and wireless value-added service Weibo in China.Leung recently said Sina's ad revenue took a significant hit in the first half of 2020, but the COVID-19 outbreak likely went a long way in highlighting the value of Weibo given the government and media outlets used it to disseminate information. Leung is calling for a 1% drop in revenue in 2020, including a 10% decline in portal ads and a 9% increase in fintech revenue.Like many other stocks, Leung is anticipating a strong recovery in the second half of the year and said user monetization, advertising, membership growth and app improvements are all bullish long-term drivers.Bank of America has a Buy rating and $57 price target for SINA stock.Latest Ratings for GWPH DateFirmActionFromTo May 2020Cantor FitzgeraldMaintainsOverweight Apr 2020Northland Capital MarketsInitiates Coverage OnOutperform Mar 2020CitigroupInitiates Coverage OnBuy View More Analyst Ratings for GWPH View the Latest Analyst Ratings See more from Benzinga * Cannabis Short Sellers Down 1M In May * Cannabis Stock Rally Puts Short Sellers In The Red For 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/28/2020
|
7 High-Risk Stocks For Market Gamblers
- Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local...
- 05/28/2020
|
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
- Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
- 05/24/2020
|
NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates
- NextCure Inc (NXTC) delivered earnings and revenue surprises of 156.90% and 1621.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/07/2020
|
NextCure Reports First Quarter 2020 Financial Results
- BELTSVILLE, Md., May 07, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
- 05/07/2020
|
NextCure to Present at BofA Securities Virtual Health Care Conference
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
- 05/06/2020
|
Goldman Sachs Group Inc. Buys 6,741 Shares of NextCure Inc (NASDAQ:NXTC)
- Goldman Sachs Group Inc. grew its stake in NextCure Inc (NASDAQ:NXTC) by 95.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,797 shares of the company’s stock after acquiring an additional 6,741 shares during the quarter. Goldman Sachs Group Inc. owned 0.06% of […]
- 04/20/2020
|
Bank of New York Mellon Corp Has $2.49 Million Holdings in NextCure Inc (NASDAQ:NXTC)
- Bank of New York Mellon Corp grew its stake in NextCure Inc (NASDAQ:NXTC) by 197.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,160 shares of the company’s stock after purchasing an additional 29,336 shares during the period. Bank of New York […]
- 04/20/2020
|
Is Studio City International Holdings Limited (MSC) A Good Stock To Buy?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/15/2020
|
Is ForeScout Technologies, Inc. (FSCT) Going to Burn These Hedge Funds?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/15/2020
|
Kronos Worldwide, Inc. (KRO): Hedge Funds Are Snapping Up
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/15/2020
|
SciPlay Corporation (SCPL): Are Hedge Funds Right About This Stock?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 04/15/2020
|
Hedge Funds Have Never Been This Bullish On NextCure, Inc. (NXTC)
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/15/2020
|
NextCure (NXTC) Gets a Buy Rating from Morgan Stanley
- Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on NextCure (NXTC) today and set a price target of $58.00. The company's shares closed last
- 04/15/2020
|
Alnylam's Blackstone Funding, And Other News: The Good, Bad And Ugly Of Biopharma
- Alnylam received $2bn funding from Blackstone. NextCure postpones trial launch due to coronavirus. Fennec Pharmaceuticals' NDA is accepted by the FDA.
- 04/14/2020
|
Needham Keeps a Buy Rating on NextCure (NXTC)
- Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC) today and set a price target of $72.00. The company's shares closed last Monday at
- 04/13/2020
|
Needham Keeps a Buy Rating on NextCure (NXTC)
- Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC – Research Report) today and set a price target
- 04/13/2020
|
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the company's clinical trial activities due to the impact of the COVID-19 pandemic. “The COVID-19 pandemic has put significant strain on our clinical trial sites, and has raised concerns around monitoring patient safety,” said Michael Richman, NextCure’s president and chief executive officer.
- 04/13/2020
|
NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on April 15th at 2:10 pm Eastern time. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
- 04/08/2020
|
Macquarie Group Ltd. Invests $5.63 Million in NextCure Inc (NASDAQ:NXTC)
- Macquarie Group Ltd. purchased a new position in shares of NextCure Inc (NASDAQ:NXTC) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the company’s stock, valued at approximately $5,633,000. Several other large investors have also modified their holdings […]
- 04/08/2020
|
NextCure Inc (NASDAQ:NXTC) Receives Consensus Rating of "Buy" from Brokerages
- Shares of NextCure Inc (NASDAQ:NXTC) have received an average recommendation of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target […]
- 04/08/2020
|
Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD
- Sofinnova Investments announces the promotions of Maha Katabi and Sarah Bhagat.
- 03/31/2020
|
NextCure appoints Garry Nicholson to board of directors NXTC;GTHX
- NextCure appoints Garry Nicholson to board of directors NXTC GTHX
- 03/30/2020
|
NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than
- 03/30/2020
|
Alliancebernstein L.P. Has $59.89 Million Stock Holdings in NextCure Inc (NASDAQ:NXTC)
- Alliancebernstein L.P. boosted its holdings in shares of NextCure Inc (NASDAQ:NXTC) by 86.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,063,278 shares of the company’s stock after buying an additional 494,467 shares during the period. Alliancebernstein L.P. owned […]
- 03/30/2020
|
Critical Comparison: Sarepta Therapeutics (NASDAQ:SRPT) versus NextCure (NASDAQ:NXTC)
- Sarepta Therapeutics (NASDAQ:SRPT) and NextCure (NASDAQ:NXTC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Insider and Institutional Ownership 93.8% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 73.1% of […]
- 03/29/2020
|
Why You Shouldn't Bet Against NextCure (NXTC) Stock
- NextCure (NXTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
- 03/26/2020
|
Blair likes Incyte in premarket analyst action
- Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares up
- 03/24/2020
|
NextCure (NXTC) Gets a Buy Rating from Needham
- Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC) today and set a price target of $72.00. The company's shares closed last Monday at
- 03/13/2020
|
NextCure (NXTC) Gets a Buy Rating from Needham
- Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC – Research Report) today and set a price target
- 03/13/2020
|
NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
- BELTSVILLE, Md., March 12, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
- 03/12/2020
|
Cowen likes Amarin in premarket analyst action
- Akero Therapeutics (NASDAQ:AKRO) initiated with Buy rating and $33 (52% upside) price target at H.C. Wainwright.Amarin (NASDAQ:AMRN) initiated with Outperform rating and $23 (57% upside) price target
- 03/02/2020
|
NextCure to Present at the 40th Annual Cowen Health Care Conference
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 40th Annual Cowen Health Care Conference in Boston on March 4 at 8:00 am. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
- 02/25/2020
|
NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York on February 25 at 9:00 am. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
- 02/18/2020
|
Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
- Michael Richman, right, is shown here with Sol Langermann at Amplimmune before that company's 2013 sale. Now at NextCure, Richman is CEO, and Langermann is chief scientific officer.
- 01/14/2020
|
NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
- BELTSVILLE, Md., Jan. 06, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
- 01/06/2020
|
3 Healthcare Stocks With 100% Street Support
- Getting everyone on board isn’t always easy. Whether out at a restaurant ordering a shared platter with friends, or choosing a song from a playlist, it can be challenging to reach an agreement with those around you, and mostly impossible to please everyone at the same time.Of course, there are exceptions to the rule, and even the analysts on Wall Street all reach the same conclusion at times. Common disagreements on whether a stock is over-sold or over-bought, are periodically put aside as a consensus is reached about one’s potential.The odds are even harder to beat when considering the future potential of stocks from the same sector, so when everyone is singing from the same hymn sheet, it’s time to take notice.With this in mind, we used TipRanks’ Analysts' Top Stocks tool to home in on 3 stocks in the same sector (healthcare in our case) which have received nothing but bullish shout outs in the last three months, and which, additionally, all have a Strong Buy consensus rating. Let’s get the lowdown.NextCure Inc (NXTC)This biotech, which develops new cancer drugs, has been turning heads on the Street recently.As is common in the sector, NextCure’s share price skyrocketed at the start of November following the release of promising data from early clinical trial results for its cancer treatment, NC318, an antibody targeting Siglec-15 (an immuno-suppressive protein of the tumor micro-environment). The news caused the share price to soar almost 250% in a single day. Roughly a week later, the stock crashed by over 50% in a session, following updated data which wasn’t quite as promising.These shenanigans are common in the volatile world of biotechs, and not much is to be deduced from the wild price swings following such early results. As it happens, in this case, NextCure’s pedigree is very strong.The company’s founder is Dr. Lieping Chen, Professor of Immunobiology at Yale University, and discoverer of the PD-L1/PD1 pathway, which showed that blocking the interaction between PD-1 and PD-L1 by monoclonal antibodies had a positive effect on the immune system’s ability to eliminate tumors.NextCure has other cancer treatment medicines in the pipeline, and BTIG’s Robert Hazlett sets out the bullish case for the recently listed biotech.The 5-star analyst noted, “NC318 has material promise as it modifies the activity of S15, a potent immunosuppressive protein, in the tumor microenvironment (TME). Normally S15 is expressed at very low levels, but in the TME, it is materially overexpressed, creating the potential for a meaninful immuno-oncology target, as it is present in 15-25% in NSCLC, TNBC, ovarian and head & neck cancers, providing NC318 with multi-billion dollar potential. NextCure is also employing its FIND-IO discovery platform toward developing other IO therapies.”Therefore, Hazlett initiated coverage on NextCure with a Buy rating, and set a price target of $61. As share prices surged at the end of last week, the upside potential comes in at a modest 4%. (To watch Hazlett’s track record, click here)Three other analysts tracked over the last 3 months all rate NextCure as a Buy, which collectively adds up to a Strong Buy consensus rating. The fellow analysts are even more bullish than Hazlett, as the average price target of $68.75 implies potential upside of 17%. (See NextCure stock analysis on TipRanks) Axsome Therapeutics Inc (AXSM)On to the Street’s next promising healthcare choice, and we encounter a recurring theme. Axsome therapeutics is up by over 115% in the last week, following -you guessed it- positive trial data.The CNS (central nervous system) focused biotech, released results for its experimental anti-depression drug, AXS-05, showing the treatment met the primary endpoint in a Phase 3 clinical trial. Axsome plans to submit an application to the FDA for approval of the therapy in the second half of 2020.The positive results back up a previous phase 2 trial in which AXS-05 exhibited superior efficacy compared to Bupropion for both MDD (major depressive disorder) and smoking cessation.BTIG’s Robert Hazlett also covers Axsome and reminds investors of the company’s potential. “Taken together, these data show consistent, rapid, durable, and significant anti-depressant effects of AXS-05 and de-risk AXS-05 in MDD; with additional strong results, we also modestly reduce our discount for AXS-05 in treatment resistant depression (TRD) as well… Given AXS-05’s relatively clear path to approval, consistent efficacy profile, and oral delivery, we now formally include M&A; exit optionality into our valuation… We believe there is evidence that AXS-05’s broad activity at multiple CNS receptors (NMDA, Sigma-1, others) has the potential to support its use in multiple large CNS indications with peak sales potential of several billion dollars,” he said.Therefore, Hazlett reiterated his Buy recommendation on Axsome, alongside a price target of $97.A full house of 9 Buys bestows on Axsome Strong Buy status. As the average price target stands at $123.50, there is further room for growth in the shape of 23%. (See Axsome stock analysis on TipRanks) iRhythm Technologies (IRTC)Digital healthcare company, iRhythm Technologies, has had a poor 2019, with its share price losing 12% year-to-date. Looking at the bigger picture, though, the cardiac device specialist still has a lot going for it.The company’s flagship product, Zio, is a wearable patch that detects cardiac symptoms and has gained quick adoption due to ease of use and accurate data readings.iRhythm’s marketing strategy of getting a foot in the door at doctors’ offices to set up new accounts, has seen use of the Zio XT patch in diagnostic situations rise from 10% of accounts at the end of 2016 to 70% by 2018’s close. A further addition of sales representatives indicates the company will see out 2019 with as many as 140 sales reps, compared to 110 at the end of 2018, and significantly more than 2017’s 86.RBC’s Brandon Henry is with the bulls on iRhythm. The 4-star analyst noted, “We believe IRTC’s core business will continue to perform well, led by new sales rep adds, increased sales rep productivity, the full commercial launch of Zio AT (which should drive additional XT sales), and continued penetration in large integrated hospitals.”To this end, Henry reiterated an Outperform rating on the medical instrument maker, alongside a price target of $109. Should the target be met, gains of almost 79% could be in line over the next 12 months. (To watch Henry’s track record, click here)Where does the Street stand on iRhythm? The Street agrees with Henry. The cardiac device developer has a Strong Buy consensus rating, based on 3 Buy recommendations. The average target price adds 50 cents to the RBC analyst’s target and comes in at $109.50, implying handsome upside potential of 80%. (See iRhythm's price targets and analyst ratings on TipRanks)
- 12/22/2019
|
Is NextCure, Inc. (NXTC) A Good Stock To Buy ?
- We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- 12/16/2019
|
NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
- 11/26/2019
|
NextCure Announces Closing of Public Offering
- BELTSVILLE, Md., Nov. 19, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
- 11/19/2019
|
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
- 11/15/2019
|
NextCure Announces Pricing of Public Offering of Common Stock
- BELTSVILLE, Md., Nov. 14, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.
- 11/15/2019
|
NextCure Announces Proposed Public Offering of Common Stock
- NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public offering of 3,200,000 shares of its common stock. In addition, NextCure intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the common stock to be sold in the offering will be offered by NextCure.
- 11/12/2019
|
